New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling.
Sarah CadotChloe AudebertCharlotte DionSoleakhena KenLoïc DupréLaetitia LargeaudCamille LaurentLoic YsebaertFabien CrausteAnne Quillet-MaryPublished in: PLoS medicine (2024)
ClinicalTrials.gov NCT02824159.